Company Encyclopedia
View More
name
CCHT
000661.SZ
Changchun High-Tech Industry (Group) Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines products in China. The company offers genetic engineering, biological vaccines, antibody drugs, chemical drugs, and modern Chinese medicine. It also develops real estate properties. The company was founded in 1993 and is based in Changchun, China.
3.157 T
000661.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking79/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.17%C
    • Profit Margin7.44%B
    • Gross Margin85.61%A
  • Growth ScoreD
    • Revenue YoY-9.72%D
    • Net Profit YoY-74.14%E
    • Total Assets YoY1.24%C
    • Net Assets YoY-0.30%C
  • Cash ScoreC
    • Cash Flow Margin1343.44%B
    • OCF YoY-9.72%D
  • Operating ScoreC
    • Turnover0.41C
  • Debt ScoreA
    • Gearing Ratio17.55%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Zhitong A-share lock-up release overview | November 4

    On November 4th, a total of 5 listed companies had their restricted shares unlocked, with a total market value of approximately 157 million yuan. The specific situation of the restricted share unlocks today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares Changchun Gaoxin 000661 Equity Incentive Restricted Circulation 42,900 Yunnai Power 000903 Equity Incentive Restricted Circulation 14,978,800 YIWU CCC 600415 Equity Incentive Restricted Circulation 795,600 Valiant 002643 Equity Incentive Restricted Circulation 7,128,800 Panlong Pharmaceutical 002864 Equity Incentive Restricted Circulation 281,600

    Zhitong·
    SH
    600415
    +1.30%
    SZ
    002643
    +0.93%
    SZ
    002864
    -2.02%
    Zhitong·
    SH
    600415
    +1.30%
    SZ
    002643
    +0.93%
    SZ
    002864
    -2.02%

    CCHT: GenSci134 injection domestic production drug registration clinical trial application approved

    CCHT's subsidiary, GenSci Pharmaceutical, has received approval from the National Medical Products Administration for the domestic production drug registration clinical trial application of GenSci134 injection. This drug is a biological product for the treatment of growth hormone deficiency, suitable for adult and pediatric patients, especially for those with idiopathic short stature

    Zhitong·
    SZ
    000661
    +0.34%
    Zhitong·
    SZ
    000661
    +0.34%

    CCHT's subsidiary has received approval for the clinical trial application for the domestic production of the injectable GenSci143 drug

    CCHT's subsidiary Changchun Jinsai Pharmaceutical recently received approval from the National Medical Products Administration to conduct clinical trials for the injectable GenSci143. This drug is a Class 1 biological product primarily used for the treatment of advanced solid tumors such as prostate cancer and lung cancer, with dual potential for targeted chemotherapy and tumor immunotherapy, aimed at overcoming tumor heterogeneity and resistance

    Zhitong·
    SZ
    000661
    +0.34%
    Zhitong·
    SZ
    000661
    +0.34%

    CCHT: Accumulated nearly 400 million yuan to repurchase company shares for incentives

    CCHT announced that the company decided to repurchase a portion of A shares through centralized bidding trading in November 2024, for the purpose of equity incentives or employee stock ownership plans, with a planned repurchase fund of 300 million to 500 million yuan, and the repurchase price not exceeding 160 yuan per share. As of October 31, 2025, the company had cumulatively repurchased 3.8945 million shares, accounting for 0.95% of the total share capital, with a highest transaction price of 112.25 yuan per share, a lowest transaction price of 84 yuan per share, and a transaction amount of 399 million yuan. The company will continue to repurchase according to the plan and disclose timely updates

    Zhitong·
    SZ
    000661
    +0.34%
    Zhitong·
    SZ
    000661
    +0.34%

    CCHT released its performance for the first three quarters, with a net profit attributable to the parent company of 1.165 billion yuan, a year-on-year decrease of 58.23%

    According to the Zhitong Finance APP, CCHT released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 9.807 billion yuan, a year-on-year decrease of 5.60%. The net profit attributable to shareholders of the listed company was 1.165 billion yuan, a year-on-year decrease of 58.23%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.269 billion yuan, a year-on-year decrease of 55.33%

    Zhitong·
    SZ
    000661
    +0.34%
    Zhitong·
    SZ
    000661
    +0.34%
    © 2025 Longbridge｜Disclaimer